HOME >> MEDICINE >> NEWS
Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial

Copenhagen, Denmark: Eagerly awaited results from the world's first head to head trial between the anti-cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol)[1] have shown that there was a better overall response rate and longer overall survival among breast cancer patients given docetaxel although docetaxel was associated with more severe side effects.

The new results were presented for the first time today (Wednesday 24 September) at ECCO 12 The European Cancer Conference taking place in Copenhagen.

Four hundred and forty nine women with advanced incurable breast cancer who had received previous treatment with an anthracycline-based chemotherapy were randomised into the Phase III trial from multiple centres across the USA between 1994 and 20012. Half were treated with paclitaxel and half were treated with docetaxel.

The trial's principal investigator, Professor Peter Ravdin, associate professor in the Department of Medicine at the University of Texas Health Science Center in San Antonio, told a news briefing that the women treated with docetaxel survived for a median 15.4 months compared with a median 12.7 months for the women who received paclitaxel.

There was an overall response rate of nearly a third among the docetaxel patients compared with a quarter for the paclitaxel patients. The median time before the breast cancer progressed (TTP) was 5.7 months for the docetaxel patients and 3.6 months for the paclitaxel patients. The results for overall survival and for TTP were statistically significantly superior for docetaxel and the overall response rate in favour of docetaxel approached statistical significance.

However, the women who received docetaxel did experience more severe side effects (grade 3/4 toxicities) with higher incidences of neutropenia (reduction in infection-fighting white blood cells), asthenia (loss of strength), infection, oedema (abnormal accumulation of fluid), mouth ulcers and neuromotor and n
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
45-3252-4163
Federation of European Cancer Societies
24-Sep-2003


Page: 1 2

Related medicine news :

1. Good intentions versus bad habits: Why the old ways win out
2. Normal aging versus Alzheimers disease and the potential for prevention
3. Regulatory T cells keep graft-versus-host disease in check
4. Study evaluates Abacavir, Lamivudine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz
5. U-M study finds new target in war against graft-versus-host disease
6. Weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) is safe and effective in patients with advanced lung cancer
7. International breast cancer prevention study launches in the United States and Canada
8. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:3/28/2015)... Centurion Service Group will be hosting a ... 2 at their Las Vegas warehouse, located at 4606 Andrews ... which consists of equipment from hospitals and surgery centers from ... PDT. , Buyers will find items of all types ... a one-stop-shop,” said Erik Tivin, CEO of Centurion. , Among ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients ... research presented today at the American Orthopaedic Society for ... study compared results for 170 patients who received rotator ... joint capsule release procedure to relieve stiffness at the ... author from St. George Hospital in Sydney, Australia. “Both ...
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... March 28, 2015 LTW Cyber is ... to collaborate for the purpose of addressing the needs ... will pursue its own opportunities to grow while seeking ... of LTW Cyber. , Ventures in LTW Cyber focus ... complemented by offerings identifying vulnerabilities and analyzing open source. ...
Breaking Medicine News(10 mins):Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a ... Complete Knee System. , ... since Zimmer first introduced the NexGen knee system, with its ... five million implantations of the NexGen knee have taken place ... knee demonstrates the importance of design innovation and component quality for ...
(Date:3/27/2015)... 2015 XRpro Sciences, Inc., a provider ... development services which features high throughput transporter and ... financial results for the year ended December 31, ... of XRpro Sciences commented, "We have completed a ... stage to commercial stage in large part by ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
Cached News: